Abstract
High-volume, big-population drugs have fueled the industry' s growth over the
past 15 years. But with increasing uncertainty about the ROI of primary care
drug development, big pharma is looking for additional avenues of growth.
Specialty Pharmaceuticals: Driving Industry Growth into the Next Decade
is a window into the complex world of specialty medicine: its stakeholders,
its evolving regulatory environment, and its economics. Based on extensive
thought-leader interviews, this report is both a manual and a guidebook to
competing and prospering in the world of specialty pharmaceuticals.
Specifically, it provides:
Strategies for . . .
- Sustaining a specialty franchise by building relationship equity with
specialists
- Identifying and communicating with hard-to-reach patient populations
- Generating referrals, raising awareness, working with disease associations
and patient groups
Data that capture . . .
- Cost, time, and approval rate comparisons between specialty and primary
care R&D
- Trends in specialty drug sales, pricing, and health care expenditures
- Specifics about the large- and small-molecule specialty pipelines in big
pharma
Insight into . . .
- Pricing and uptake prospects for biogenerics and orally delivered proteins
- The impact on practice economics of Medicare CAP and the shift away from
buy-and-bill
- Positioning specialty products for managed care
Specialty Pharmaceuticals: Driving Industry Growth into the Next Decade
delivers the case studies, the recommendations, and the insider insights to
help you navigate the shifting terrain of specialty markets: the gathering
cost pressures, rising competitive heat, disruptive technologies, changing
regulatory guidelines, new reimbursement paradigms, and more. The report also
drills down into two specialty disease commercial opportunities -- pulmonary
arterial hypertension and scleroderma -- detailing the epidemiology, the drugs
in development, and the opportunities for improving on the current standard of
treatment.
| 
View Cart
